Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

F. Spagnolo · SciRah

Researcher profile · Semantic Scholar

F. Spagnolo

Share profile

F. Spagnolo — researcher profile on SciRah

h-index: 37
Works: 163
Citations: 4,743

Most-cited papers

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
A. Cortellini, M. Tucci, V. Adamo, L. S. Stucci +36 more
2020Journal for ImmunoTherapy of Cancer239 citations Open access
Semantic Scholar
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
P. Ascierto, M. Mandalà, P. Ferrucci, M. Guidoboni +26 more
2022Journal of Clinical Oncology200 citations Open access
Semantic Scholar
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
G. Long, J. Luke, M. Khattak, L. de la Cruz Merino +20 more
2022The Lancet Oncology127 citations
Semantic Scholar
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
A. Baggi, P. Quaglino, M. Rubatto, R. Depenni +22 more
2021European Journal of Cancer104 citations Open access
Semantic Scholar
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
S. Buti, M. Bersanelli, F. Perrone, M. Tiseo +43 more
2020European Journal of Cancer103 citations Open access
Semantic Scholar
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
P. Queirolo, A. Boutros, E. Tanda, F. Spagnolo +1 more
2019Seminars in Cancer Biology97 citations Open access
Semantic Scholar
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
P. Ascierto, M. Casula, J. Bulgarelli, M. Pisano +33 more
2024Nature Communications95 citations Open access
Semantic Scholar
Current State of Target Treatment in BRAF Mutated Melanoma
E. Tanda, I. Vanni, A. Boutros, V. Andreotti +3 more
2020Frontiers in Molecular Biosciences94 citations Open access
Semantic Scholar
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
J. Luke, P. Ascierto, M. Khattak, L. de la Cruz Merino +16 more
2024Journal of Clinical Oncology87 citations Open access
Semantic Scholar
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
R. Dummer, P. Queirolo, Pauline Gerard Duhard, Youyou Hu +11 more
2023The Lancet Oncology70 citations
Semantic Scholar
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer.
A. Cortellini, A. D'Alessio, S. Cleary, S. Buti +54 more
2023Clinical Cancer Research70 citations Open access
Semantic Scholar
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study.
O. Nigro, G. Pinotti, F. de Galitiis, F. Di Pietro +47 more
2020medRxiv65 citations Open access
Semantic Scholar
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
I. Vanni, E. Tanda, F. Spagnolo, V. Andreotti +2 more
2020Frontiers in Molecular Biosciences58 citations Open access
Semantic Scholar
Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
A. Boutros, M. Bruzzone, E. Tanda, E. Croce +6 more
2021European Journal of Cancer47 citations Open access
Semantic Scholar
Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
A. Boutros, E. Tanda, E. Croce, F. Catalano +10 more
2023European Journal of Cancer41 citations Open access
Semantic Scholar
Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1
L. Pastorino, V. Andreotti, B. Dalmasso, I. Vanni +27 more
2020Cancers37 citations Open access
Semantic Scholar
Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
I. Vanni, E. Tanda, B. Dalmasso, L. Pastorino +5 more
2020Frontiers in Molecular Biosciences35 citations Open access
Semantic Scholar
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma
M. Guida, N. Bartolomeo, D. Quaresmini, P. Quaglino +16 more
2022Journal of Translational Medicine34 citations Open access
Semantic Scholar
Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma
A. Boutros, F. Cecchi, E. Tanda, E. Croce +4 more
2021Frontiers in Oncology32 citations Open access
Semantic Scholar
Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients
G. Ciccarese, B. Dalmasso, W. Bruno, Paola Queirolo +11 more
2020Journal of Translational Medicine32 citations Open access
Semantic Scholar
The adjuvant treatment revolution for high-risk melanoma patients.
F. Spagnolo, A. Boutros, E. Tanda, P. Queirolo
2019Seminars in Cancer Biology32 citations
Semantic Scholar
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
M. Guida, N. Bartolomeo, P. Quaglino, G. Madonna +15 more
2021Cancers31 citations Open access
Semantic Scholar
Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review
F. Spagnolo, A. Boutros, E. Croce, F. Cecchi +4 more
2021European Journal of Clinical Investigation29 citations Open access
Semantic Scholar
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
Mario Mandalá, P. Lorigan, M. C. Sergi, N. Benannoune +25 more
2024European Journal of Cancer28 citations Open access
Semantic Scholar
The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts
I. Stanganelli, F. Spagnolo, G. Argenziano, P. Ascierto +11 more
2022Cancers28 citations Open access
Semantic Scholar
HO‐1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition
A. Furfaro, S. Ottonello, Giulia Loi, Irene Cossu +9 more
2020International Journal of Cancer28 citations Open access
Semantic Scholar
How I perform fertility preservation in breast cancer patients
M. Razeti, S. Spinaci, F. Spagnolo, C. Massarotti +1 more
2021ESMO Open27 citations Open access
Semantic Scholar
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
F. Spagnolo, A. Boutros, F. Cecchi, E. Croce +2 more
2021BMC Cancer26 citations Open access
Semantic Scholar
Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab.
M. Pistillo, R. Carosio, F. Grillo, V. Fontana +11 more
2020Clinical Immunology26 citations
Semantic Scholar
Italian survey on managing immune checkpoint inhibitors in oncology during COVID‐19 outbreak
M. Tagliamento, F. Spagnolo, F. Poggio, Davide Soldato +7 more
2020European Journal of Clinical Investigation25 citations Open access
Semantic Scholar
Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?
E. Tanda, A. L. d'Amato, G. Rossi, E. Croce +4 more
2021Frontiers in Oncology24 citations Open access
Semantic Scholar
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
M. Khattak, J. Luke, G. Long, P. Ascierto +20 more
2022European Journal of Cancer23 citations Open access
Semantic Scholar
How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma
Mariarosaria Marseglia, A. Amaro, N. Solari, R. Gangemi +6 more
2021Cancers23 citations Open access
Semantic Scholar
Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization
L. Mastracci, V. Fontana, P. Queirolo, R. Carosio +12 more
2020Cancer Immunology and Immunotherapy22 citations
Semantic Scholar
Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup
W. Bruno, B. Dalmasso, M. Barile, V. Andreotti +29 more
2022ESMO Open20 citations Open access
Semantic Scholar
Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis
L. Arecco, E. Blondeaux, M. Bruzzone, M. Ceppi +13 more
2022Human Reproduction19 citations Open access
Semantic Scholar
NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma.
P. Ascierto, P. Bossi, M. Mandalà, P. Queirolo +12 more
2023Journal of Clinical Oncology18 citations
Semantic Scholar
CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients
B. Dalmasso, L. Pastorino, G. Ciccarese, V. Andreotti +7 more
2019Journal of American Academy of Dermatology18 citations
Semantic Scholar
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in Melanoma.
P. Ascierto, Mario Mandalá, P. F. Ferrucci, M. Guidoboni +33 more
2024NEJM Evidence17 citations Open access
Semantic Scholar
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
J. Luke, P. Ascierto, M. Khattak, L. de la Cruz Merino +16 more
2023Journal of Clinical Oncology16 citations
Semantic Scholar
Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma
A. Amaro, R. Gangemi, L. Emionite, P. Castagnola +7 more
2023Cancers15 citations Open access
Semantic Scholar
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort
D. Santini, T. Zeppola, M. Russano, F. Citarella +44 more
2021Journal of Translational Medicine15 citations Open access
Semantic Scholar
Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience
A. Crispo, M. Corradin, E. Giulioni, A. Vecchiato +33 more
2021Frontiers in Oncology14 citations Open access
Semantic Scholar
Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient
A. Boutros, Chiara Schiavi, F. Cecchi, F. Spagnolo +5 more
2020Frontiers in Immunology14 citations Open access
Semantic Scholar
Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma.
E. de Simoni, F. Spagnolo, S. Gandini, A. Gaeta +5 more
2024Cancer Treatment Reviews13 citations
Semantic Scholar
Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study.
Mario Mandalá, Teresa Amaral, P. Rutkowski, M. C. Sergi +27 more
2025European Journal of Cancer11 citations Open access
Semantic Scholar
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
R. Dummer, P. Queirolo, Ana Maria Abajo Guijarro, Youyou Hu +11 more
2022The Lancet Oncology11 citations
Semantic Scholar
Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors?
E. Tanda, E. Croce, F. Spagnolo, L. Zullo +3 more
2021Frontiers in Oncology11 citations Open access
Semantic Scholar
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study
L. Cantini, F. Paoloni, Federica Pecci, F. Spagnolo +47 more
2023Journal of the National Cancer Institute10 citations Open access
Semantic Scholar
The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors
A. Boutros, R. Carosio, Dalila Campanella, F. Spagnolo +10 more
2023Immuno-Oncology Technology9 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Tanda×27
Invite
E. Tanda — researcher profile on SciRah
P. Queirolo×25
Invite
P. Queirolo — researcher profile on SciRah
P. Ascierto×20
Invite
P. Ascierto — researcher profile on SciRah
A. Boutros×14
Invite
A. Boutros — researcher profile on SciRah

×11

Invite

F. Cecchi — researcher profile on SciRah

Invite

M. Tucci — researcher profile on SciRah

M. Del Vecchio×9

Invite

M. Del Vecchio — researcher profile on SciRah

Invite

E. Croce — researcher profile on SciRah

Invite

D. Mallardo — researcher profile on SciRah

Invite

P. Quaglino — researcher profile on SciRah

A. Cortellini×7

Invite

A. Cortellini — researcher profile on SciRah

A. Botticelli×7

Invite

A. Botticelli — researcher profile on SciRah